<div id="readability-page-1"><div>(Alliance News) - Hutchmed China Ltd on Wednesday said the results from its SACHI phase-three lung cancer trial have been published in medical journal the Lancet.Hutchmed China explained that the study looked at savolitinib and osimertinib in combination for the treatment of &#34;locally advanced or metastatic epidermal growth factor receptor mutation-positive non-small cell lung cancer with MET amplification after disease progression on first-line EGFR tyrosine kinase inhibitor therapy&#34;.MET is a tyrosine kinase receptor that has an essential role in normal cell development, said Hutchmed China.The Hong Kong-based developer of treatments for cancer and immunological diseases said savolitinib is an oral, potent and highly selective MET TKI. It is being jointly developed by Hutchmed and Cambridge, England-based pharmaceutical company AstraZeneca PLC, and commercialised by AstraZeneca. Osimertinib is a third-generation, irreversible EGFR TKI, added Hutchmed China. The company said the study was the first randomised phase three trial that confirmed the efficacy of MET inhibition in patients with &#34;advanced NSCLC and acquired MET amplification after progression on prior EGFR-TKI treatment&#34;. Hutchmed China said interim data from the trial led to the combination being approved in China in June last year. Shares in Hutchmed China were down 0.5% at 220.00 pence around midday on Wednesday in London. &#34;The SACHI trial, now published in The Lancet, provides compelling evidence that savolitinib combined with osimertinib can transform outcomes for patients with EGFR-mutated NSCLC with MET amplification. These findings highlight the combination's ability to address MET amplification, a critical resistance mechanism, offering clinically meaningful improvements for this challenging patient population,&#34; said Shun Lu, chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, School of Medicine, Shanghai Jiaotong University, and co-leading Principal Investigator of the SACHI trial. By Christopher Ward, Alliance News reporterComments and questions to newsroom@alliancenews.comCopyright 2026 Alliance News Ltd. All Rights Reserved.</div></div>

和黄医药

和黄医药（Hutchmed China Ltd）宣布，其 SACHI 三期肺癌试验的结果已在《柳叶刀》（The Lancet）上发表。该试验研究了 savolitinib 和 osimertinib 联合治疗具有 MET 扩增的晚期非小细胞肺癌的效果。这是首个确认 MET 抑制在该患者群体中有效性的随机三期试验。该联合治疗于去年六月在中国获得批准。公告发布后，和黄医药的股价下跌 0.5%，至 220.00 便士

和黄医药对《柳叶刀》上发表的肺癌试验结果表示赞赏